Leo Snel
Plus aucun poste en cours
Profil
Leo Snel formerly worked at ZymoGenetics, Inc., as Senior Director-Analytical Sciences, Novo Nordisk, Inc., as Director-Biologics Development, and BioMimetic Therapeutics, Inc., as Vice President-R&D Protein Biochemistry from 2007 to 2009.
Mr. Snel received his graduate degree from Technical University of Denmark.
Anciens postes connus de Leo Snel
Sociétés | Poste | Fin |
---|---|---|
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | Corporate Officer/Principal | - |
Novo Nordisk, Inc.
Novo Nordisk, Inc. BiotechnologyHealth Technology Novo Nordisk, Inc. operates diabetes care company. It offers biopharmaceuticals, chronic weight management, human growth hormone therapy and hemophilla management services. The firm also provides rare bleeding disorders, growth hormone related disorders, and women's health. The company was founded in 1982 and is headquartered in Plainsboro, NJ. | Corporate Officer/Principal | - |
BioMimetic Therapeutics, Inc.
BioMimetic Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology BioMimetic Therapeutics, Inc. developed and sells protein therapeutics for tissue and organ regeneration. The company was founded by Samuel E. Lynch and David M. Renzi on April 14, 1999 and was headquartered in Franklin, TN. | Directeur Technique/Scientifique/R&D | - |
Formation de Leo Snel
Technical University of Denmark | Graduate Degree |
Expériences
Fonctions occupées
Sociétés liées
Entreprise privées | 3 |
---|---|
BioMimetic Therapeutics, Inc.
BioMimetic Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology BioMimetic Therapeutics, Inc. developed and sells protein therapeutics for tissue and organ regeneration. The company was founded by Samuel E. Lynch and David M. Renzi on April 14, 1999 and was headquartered in Franklin, TN. | Health Technology |
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | Health Technology |
Novo Nordisk, Inc.
Novo Nordisk, Inc. BiotechnologyHealth Technology Novo Nordisk, Inc. operates diabetes care company. It offers biopharmaceuticals, chronic weight management, human growth hormone therapy and hemophilla management services. The firm also provides rare bleeding disorders, growth hormone related disorders, and women's health. The company was founded in 1982 and is headquartered in Plainsboro, NJ. | Health Technology |